Dana-Farber Cancer Institute v. Ono Pharmaceutical Co., Ltd., No. 19-2050 (Fed. Cir. July 14, 2020)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

Ono Pharmaceutical Co. Ltd., Tasuku Honjo, E.R. Squibb & Sons, L.L.C., and Bristol-Myers Squibb Co. (col- lectively, “Ono”) appeal from the judgment of the United States District Court for the District of Massachusetts af- ter a bench trial ordering that Dr. Gordon Freeman and Dr. Clive Wood be added to U.S. Patents 7,595,048 (“the ’048 patent”), 8,168,179 (“the ’179 patent”), 8,728,474 (“the ’474 patent”), 9,067,999 (“the ’999 patent”), 9,073,994 (“the ’994 patent”), and 9,402,899 (“the ’899 patent”) as co-inventors. Dana-Farber Cancer Inst., Inc. v.